About

➀ Read and Learn

The following course content

Introduction   

In 1935, Hall and O’Toole isolated Clostridioides difficile (C. diff) from the stool of a healthy infant [1]. The identified organism became a leading cause of nosocomial antibiotic-associated illness in Europe and North America causing a range of symptoms from mild diarrhea to severe life-threatening pseudomembranous colitis and toxic megacolon [1] [21].  

Clostridioides difficile (C. difficile), once referred to as Clostridium difficile, is a rod-shaped Gram-positive, toxin-producing anaerobe that can exist in two forms: a vegetative state and a spore state [5]. C. diff produces two exotoxins: toxin A (TcdA) and toxin B (TcdB) [6]. These toxins interfere with the cytoskeletal structure and the tight junctions of target cells, leading to cell rounding and cell death [10]. The spore form (dormant) of C. difficile is robust, enabling the bacterium to survive under extreme conditions and resist standard sterilization techniques [1].  

The spores are impervious to heat, acid, ultraviolet radiation, aggressive chemicals, and antibiotics [1]. The antibiotic-resistant nature of the spores allows them to remain in the gastrointestinal tract, which can result in recurring infections even after the elimination of the vegetative form of C. difficile [7]. Despite ongoing efforts to enhance prevention and control its spread in healthcare facilities, Clostridioides difficile infection (CDI) continues to be a predominant source of hospital-acquired antibiotic-associated diarrhea in the United States and other developed countries [2].  

Clostridioides difficile is notable in healthcare settings due to its association with antibiotic use, its capability to cause recurrent infections and the organism’s ability to survive on non-living surfaces (fomites) for extended periods [1][9]. The hospital setting is a significant mediator in the spread of healthcare-associated infections [9]. Recent surges in C. difficile infections have resulted in heightened morbidity and mortality rates secondary to the emergence of a new hypervirulent strain, identified as BI/NAP1/027 (Strain 027) [4]. This strain produces enhanced toxin production compared to historical strains of C. difficile [4]. 

Research calculates the economic burden of C. difficile in the United States to be approximately $5.4 billion, with around $4.7 billion of this cost arising within healthcare facilities secondary to hospitalizations and recurring infections [8]. In patients experiencing a primary C. difficile infection, the average healthcare cost is $43,718, in contrast to $19,513 for patients without C. difficile. Breaking down the costs by care settings, the inpatient expenses for those with C. difficile infection averaged $28,014, compared to $6,918 for those without the infection [8].  

In cases of recurrent C. difficile infection, the average healthcare expense is $49,456, while it was $38,876 for matched patients without the infection [8]. Research indicates that the total healthcare cost associated with recurrent C. difficile infection, as opposed to a primary infection is $10,500 [8]. 

Case Study: Complicated Clinical Manifestations of C. difficile Infection 

Patient Profile 

• Age/Gender: 65-year-old male 

• Medical History: Hypertension, Type 2 Diabetes 

• Hospitalization History: Recent hospitalization for hip replacement surgery, received broad-spectrum antibiotics for post-op infection management. 

Clinical Presentation 

• Asymptomatic Period: Patient was an asymptomatic carrier post-discharge. 

• Onset of Symptoms: 10 days post-discharge, the patient reported: watery diarrhea with occasional mucus Mild abdominal pain Low-grade fever Anorexia and nausea. 

• Week 2: Symptoms worsened with increased diarrhea frequency, and the presence of occult blood. 

• Week 3: Development of severe abdominal pain, vomiting, and significant dehydration. 

Diagnostic Workup 

• Stool Tests: Positive for C. difficile toxins. 

• Blood Tests: Elevated white blood cell count, signs of dehydration. 

• Imaging: Abdominal CT indicated colonic wall thickening. 

Differential Diagnosis 

• Consider infectious colitis, inflammatory bowel disease, and ischemic colitis. 

Treatment and Management 

• Initial Approach: Metronidazole initiated, with fluid replacement therapy. 

• Week 4: Lack of improvement led to the introduction of oral vancomycin. 

Complications 

• Fulminant Colitis Development: Rapid deterioration with diffuse abdominal pain, significant abdominal distension, and hypovolemia. 

• Hospital Readmission: Required for management of potential sepsis and toxic megacolon. 

• Surgical Consultation: For the risk of perforated bowel and peritonitis. 

Distinctive Aspect of the Case 

• Rare Presentation: Patient developed protein-losing enteropathy (ongoing damage or irritation). 

• Extra-Colonic Manifestations: Reactive arthritis occurred during the infection. 

Outcome 

• Successful Management: The patient responded to a combination of antibiotic therapy, fluid resuscitation, and close monitoring for complications. 

• Recurrent Infection: Experienced a recurrence of symptoms 2 months later and managed with 

• a tapered-pulsed (T-P) fidaxomicin regimen [41]. 

Discussion 

This case highlights the spectrum of C. difficile infection, from an asymptomatic carrier state to severe complications including fulminant colitis and extra-colonic manifestations. The case underscores the importance of early recognition, prompt treatment, and consideration of rare presentations in clinical practice. The recurrent nature of C. difficile infection emphasizes the need for ongoing vigilance and novel treatment strategies in management. 

Epidemiology 

Clostridioides difficile (CD) is the predominant cause of infectious diarrhea associated with healthcare settings worldwide [11]. The occurrence of Clostridioides difficile infection and related hospital admissions saw a rise in the 2000s. This increase was due to the emergence of the epidemic strain ribotype 027 [13]. From 1996 to 2003, the rate of discharge diagnoses for Clostridioides difficile infections CDI climbed from 31 to 61 cases per 100,000 individuals per year.  

The estimated prevalence of C. difficile infection in the United States decreased between 2011 and 2017. [13]. This led to a 24% decrease in the overall adjusted burden of all hospitalizations for C. difficile infection, as reported in the Centers for Disease Control and Prevention’s (CDC) Antibiotic Resistance Threats in the United States, 2019 [13]. CDI imposes considerable clinical, social, and economic burdens. Although the incidence of healthcare-associated CDI has decreased, cases of community-associated CDI are increasing [14]. The United States now sees an estimated 500,000 cases of CDI each year with about 30,000 of these cases resulting in death [1] [14].  

Recurrent C. difficile infection (rCDI) often occurs following successful treatment of an initial CDI episode [15]. rCDI is an episode of CDI that occurs within 8 weeks after a prior episode [15]. It may arise from a relapse of the initial CDI with the same strain or a reinfection with a different strain. Recurrent infections are a significant concern, with between 15% to 30% of patients experiencing a recurrence after the initial episode [15]. Recurrences are more common in the elderly, those with comorbid conditions, and individuals with a history of multiple antibiotic exposures [15]. 

Despite C. difficile being a hospital-acquired infection, community-acquired infections account for 41% of the infections [15]. Studies have also indicated a shifting trend with an increased incidence of C. difficile infection among younger patients and patients without prior exposure to antibiotics [15].  

The misuse of antibiotics heightens the risk of C. difficile infections in patients. Over half of hospitalized patients receive antibiotics, with 30% to 50% of these prescriptions being unnecessary or inappropriate [16]. The CDC estimates that up to $3.8 billion in saved medical costs over a period of 5 years through better antibiotic management [16]. 

Pathophysiology 

Antibiotic treatment can disrupt the natural microbial balance in the intestines, paving the way for C. difficile colonization and subsequent toxin production, which damages the colonic epithelial cells [3]. C. diff is a spore-forming, toxin-producing bacterium which colonizes in the large intestines after a disruption in normal gut flora [17]. The underlying mechanisms of recurrent CDIs include the continued presence of C. diff spores, insufficient immune responses, and changes in the gut microbiota [17].  

Toxins released by C. diff can cause inflammation, harm the intestinal lining, and result in diarrhea [17]. Adults with a robust immune system often become asymptomatic carriers. Neonates show a high asymptomatic carrier rate due to their lack of specific intestinal receptors for C. difficile [17]. The characteristic symptoms of C. difficile, infection, diarrhea, and colitis, occur secondary to the clostridial glycosylation exotoxins. These include toxin A (TcdA), an enterotoxin, and toxin B (TcdB), which is cytotoxic [17]. 

Clinical Signs and Symptoms 

The clinical manifestations of CDI vary from mild diarrhea to severe, fatal conditions such as pseudomembranous colitis or toxic megacolon [18]. Although antibiotics remain the primary treatment for CDI, recent years have seen the emergence of new therapies, including antibodies targeting C. difficile toxin B and fecal microbial transfer (FMT) [19]. These treatments highlight the significance of native bacterial flora in both preventing disease in healthy individuals and contributing to disease pathogenesis when disrupted by antibiotics.  

The initial and most frequent symptom of a C. difficile infection is watery diarrhea [20]. In mild cases, this involves diarrhea occurring at least three times daily accompanied by abdominal cramping or tenderness [20]. As the infection progresses in severity, the frequency of diarrhea can increase to 10 to 15 times daily [20]. Patients may also observe signs of blood in their stool (hematochezia) along with continuous abdominal pain, watery diarrhea, abdominal distension, nausea, and vomiting, anorexia, fever, and an increased heart rate (tachycardia) [20].

Etiology

C. difficile, a gram-positive, spore-forming found in various environments, including water, air, soil, and on surfaces in hospitals [17]. It is also present in human and animal feces. This organism thrives best at a temperature around 37 degrees Celsius. Transmission of the disease occurs most often through the fecal-oral route. Most strains causing C. difficile infection produce both toxin A and toxin B, though there have been global reports of strains limited to producing toxin B [21].

Two major clostridial glucosylating toxins drive the development of C. difficile infection, toxin A (TcdA) and toxin B (TcdB). While many pathogenic strains associated with C. difficile infection produce both toxin A (TcdA) which is enterotoxin, and toxin B (TcdA), there are reports of strains that produce only toxin B [21]. Some strains produce a third toxin, known as binary toxin C. difficile transferase (cytolethal distending toxin), which can also play a role in enhancing the virulence and severity of the disease [22]. These toxins target the colonic epithelium and immune cells, triggering a series of cellular reactions that lead to fluid secretion, inflammation, and tissue damage, which are the defining characteristics of this condition [21]. 

Risk Factors for Disease 

Antibiotic use remains the leading risk factor for C. difficile infection [3] [16]. The disruption of the intestinal microbiota by antibiotics is long-lasting, and risk of CDI increases both during therapy and in the 3-month period following cessation of therapy.  

Penicillin, cephalosporins, fluoroquinolone, and clindamycin are classes of antibiotics implicated in the disease’s cause [23]. Research indicates that clindamycin and later-generation cephalosporins are among the most common antibiotics to increase the risk of C. diff infection, while minocycline and doxycycline have a lower risk of this infection [36]. 

Apart from antibiotic usage, other risk factors involved in the causation include advanced age (above 65), chemotherapy, use of proton pump inhibitors, chemotherapy, chronic renal disease, chronic liver disease, community-living environment, previous C. difficile infection, malnutrition, history of inflammatory bowel disease (IBD) or surgery involving the intestines including the manipulation of the gastrointestinal tract (tube feeding) [24] [25].  

The rising risk of acquiring C. difficile with each day of hospital stay implies that the length of hospitalization might serve as an indicator for the extent and duration of exposure to the organism, the probability of encountering antibiotics, and the seriousness of the underlying illness [26]. The risk of CDI peaks, showing a 7- to 10-fold increase, during and within the first month following antibiotic exposure [27].  

Vitamin D could play a significant role in safeguarding against CDI, as low levels are an independent risk factor for various groups, including general patients with community-associated disease, older individuals, and patients suffering from underlying inflammatory bowel disease [28].  

Proton Pump Inhibitors (PPIs) are associated with an increased risk of C. difficile infection, as they can alter the stomach’s natural acidity, creating a more favorable environment for the bacteria to thrive [26]. In a retrospective analysis involving 754 patients with healthcare-associated CDI, ongoing use of Proton Pump Inhibitors (PPIs) indicated a 50% higher risk of recurrence. In comparison, re-exposure to antibiotics was associated with a lower increase in risk, at 30% [26].  

Long-Term Impact 

Recurrent C. difficile (rCDI) is a gastrointestinal infection caused by C. difficile bacteria and linked to dysbiosis, or imbalance, of the gastrointestinal microbiome [38]. Long term complications include an increased risk of chronic gastrointestinal discomfort, a higher likelihood of hospital readmission, and potential for severe complications like toxic megacolon, bowel perforation, and sepsis [14].  

The psychological impact, including anxiety and depression, and the financial burden on both patients and the healthcare system are significant [14]. Patients at substantial risk for poor outcomes might benefit from earlier, more aggressive strategies to restore or maintain the microbiome including fecal microbiota transplantation [30] [31].  

Symptoms analogous to irritable bowel syndrome (IBS) occur with greater frequency post-CDI with estimates that 25% experience IBS-like symptoms for at least six months following successful treatment [32]. Ongoing gastrointestinal symptoms can interfere with nutrient absorption, leading to deficiencies that can impact overall health [40].  

Additional research revealed heightened levels of fear and anxiety, as indicated by a threefold increase of depression among respondents compared to the general US adult population [33]. Patients who have experienced an episode of Clostridioides difficile infection (CDI) may continue to be at risk for gastrointestinal symptoms associated with CDI for a period of up to two years [40].  

It is important for healthcare professionals to be aware of these potential long-term complications when managing patients with C. diff infections. This knowledge is crucial for effective patient education, management, and support. 

Treatment 

The initial step in managing CDI involves discontinuing the triggering antibiotic treatment [34]. According to the clinical practice guidelines from the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), treatment for initial CDI episodes depends on disease severity [26]. 

For non-severe cases (white blood cell count ≤15.0 × 10^9/L and serum creatinine level <1.5 mg/dL), three treatment options include: 

• Vancomycin 125 mg orally, four times daily for 10 days [26]. 

• Fidaxomicin 200 mg orally, twice daily for 10 days [26]. 

• Metronidazole 500 mg orally, three times daily for 10 days (if vancomycin or fidaxomicin are not available) [26]. 

For severe cases (white blood cell count >15.0 × 10^9/L or serum creatinine level >1.5 mg/dL), two treatment options include: 

• Vancomycin 125 mg orally, four times daily for 10 days [26]. 

• Fidaxomicin 200 mg orally, twice daily for 10 days [26]. 

Fulminant CDI cases, characterized by symptoms like hypotension, shock, ileus, or toxic megacolon: 

• Oral vancomycin 500 mg or via nasogastric tube four times a day, alongside intravenous metronidazole 500 mg every 8 hours [26]. 

Research Findings 

Recent research focuses on understanding the microbiome’s role in CDIs and recurrent infections. A disturbance in the composition and function of the gut microbiome diminishes this colonization resistance, a factor linked to various gastrointestinal and non-gastrointestinal illnesses [39]. A notable instance of this is the occurrence of Clostridioides difficile infection (CDI) and its recurrent episodes, which often arise following dysbiosis induced by systemic antibiotic use [39].  

Studies have shown that a diverse gut microbiota is protective against CDIs, and efforts to develop microbiome-based therapies are underway [39]. The U.S. Food and Drug Administration (FDA) has approved VOWST™, a microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial [38].  

Probiotics and fecal microbiota transplantation (FMT) are emerging as effective strategies for restoring gut flora balance [36]. Recent guidelines emphasize the importance of antibiotic stewardship and infection control measures in preventing CDIs [37]. 

Conclusion

Recurrent C. diff infections pose a significant challenge in healthcare, with profound long-term impacts on patient health and healthcare resources [14]. Understanding the risk factors and pathophysiology of these infections is crucial in developing effective prevention and treatment strategies [14]. The treatment and management of Clostridioides difficile infection (CDI) should be comprehensive, encompassing pharmacological approaches and a holistic consideration of the patient’s experience.  

This includes addressing the psychological and social impacts during and after CDI, as well as exploring avenues for financial support, supportive services, and options for medical leave from work [14]. From the perspective of healthcare resources and institutions, it is critical to focus on reducing costs and mitigating fiscal losses that arise from reimbursement penalties and employ measures to prevent recurrent CDI (rCDI) and community-acquired CDI. Future research in microbiome science and new therapeutic approaches holds promise for better management of this burdensome condition.  

➁ Complete Survey

Give us your thoughts and feedback

➂ Click Complete

To receive your certificate